BFM
OKUR

Boothbay Fund Management’s OnKure Therapeutics OKUR Stock Holding History

Boothbay Fund Management’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,350
Closed -$166K – 1980
2023
Q4 		$166K Buy
+10,350
New +$645K ﹤0.01% 1363

Other funds holding OKUR

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Boothbay Fund Management's OKUR Position: Q2 2025 in Review

Boothbay Fund Management sold out of OnKure Therapeutics (OKUR) in Q2 2025, closing a stake of 78,021 shares — an estimated $335K sold.

Boothbay Fund Management first reported a position in OKUR in Q3 2021 and held it in 11 quarters. The position peaked at $671K in Q4 2024. 49 funds tracked by Wall St. Rank hold OKUR as of Q2 2025.

  • Boothbay Fund Management reported no remaining OnKure Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 78,021 OnKure Therapeutics shares in Q2 2025, an estimated $335K.
  • Boothbay Fund Management first reported a position in OnKure Therapeutics in Q3 2021 and held it in 11 quarters.
  • Boothbay Fund Management's OnKure Therapeutics position peaked at $671K in Q4 2024.
  • 49 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2025.

Based on Boothbay Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.